Janssen Biotech, Inc.
800 Ridgeview Drive
Horsham, PA 19044

November 14, 2011

To:
BTG International Ltd.
5 Fleet Place, London, UK, EC4M 7RD

Re: U.S. Patent No. 5,604,213

To Whom It May Concern,

This will acknowledge the approval by the FDA of NDA No. 202379 for ZYTIGA™ (abiraterone acetate) on April 28, 2011. NDA 202379 was submitted by Ortho Biotech Oncology Research and Development, Unit of Cougar Biotechnology, Inc., (Ortho) Agent of Centocor Ortho Biotech Inc. (COBI) on December 18, 2010 and references IND 71023 filed December 19, 2005. On July 5, 2011, Ortho submitted a letter to FDA informing them that COBI's name has changed to Janssen Biotech, Inc. (JBI), effective June 22, 2011.

Each tablet of the approved product, ZYTIGA, contains 250 mg abiraterone acetate. ZYTIGA, in combination with prednisone, is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC) who have received prior chemotherapy containing docetaxel. The chemical names for abiraterone acetate are 3β-acetoxy-17-(3-pyridyl)androsta-5,16-diene and (3β)-17-(3-pyridinyl)androsta-5,16-dien-3-yl-acetate. Abiraterone acetate is covered by one or more claims of US Patent 5,604,213 (the '213 patent) assigned to BTG International, Ltd.

JBI hereby authorizes BTG International Ltd. to rely on the activities of Ortho, COBI, and JBI before the FDA in submitting an application for Patent Term Extension of the '213 patent.

Very Truly Yours,

Robert Bazemore, Jr.
President